A wholly owned subsidiary of Solvay Pharmaceuticals, Inc. (9014905), Unimed Pharmaceuticals, Inc. (6806472), has settled all pending patent litigation with Watson Pharmaceuticals, Inc. (NYSE: WPI) and Paddock Laboratories (16236904) /Par Pharmaceutical Companies, Inc. (NYSE: PRX) in connection with each company's Abbreviated New Drug Application (ANDA) for a generic version of AndroGel® (testosterone gel)1% CIII.
Read more details from the press release.
AndroGel® is USFDA-approved for replacement therapy in men with conditions associated with a deficiency or absence of endogenous testosterone (a pdf file) and Unimed Pharmaceuticals holds the
[Photo Credit: androgel.com]
Comment Preview